STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
chemistry

Mira Pharmaceuticals Approves Acquisition of SKNY, Creating $60M+ Biotech Platform

byLuca Blaumann
May 8, 2025
in Pharmaceuticals, Small-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Board approves merger following independent valuation; SKNY to contribute $5M in cash or assets at closing

Mira Pharmaceuticals (MIRA), a clinical-stage company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, has announced that its Board of Directors has unanimously approved the acquisition of SKNY Pharmaceuticals, Inc. The deal follows independent valuations of both companies and sets a combined enterprise value exceeding $60 million.

The strategic merger includes a $5 million contribution from SKNY to Mira in either cash or other assets, which will be transferred at closing. A filing with the U.S. Securities and Exchange Commission is underway to obtain shareholder approval.

According to independent analysis by Moore Financial Consulting, SKNY Pharmaceuticals was assigned an enterprise value of $30.5 million, based on the risk-adjusted net present value (rNPV) of its lead compound, SKNY-1. Mira itself was valued at $30 million, creating a solid foundation for a unified company with complementary pipelines and commercial potential.

“This merger brings together two pipelines, two market opportunities, and one unified strategy,” said Erez Aminov, CEO of Mira. “Our focus remains on developing first-in-class therapies that target critical and underserved health needs.”

The centerpiece of SKNY’s pipeline is SKNY-1, an investigational oral compound that modulates cannabinoid receptors CB1 and CB2, as well as monoamine oxidase B (MAO-B)—an enzyme linked to dopamine metabolism and addiction. The compound is being developed for both obesity and nicotine dependence, two global health challenges with limited treatment options.

Industry projections underscore the market potential:

  • The global weight loss drug market is expected to surpass $150 billion by 2030, with increasing demand for alternatives to injectable GLP-1 therapies (Reuters).
  • The U.S. smoking cessation market is forecast to grow from $28.11 billion in 2024 to $50.90 billion by 2030, at a CAGR of 10.4% (Grand View Research).

Dr. Angel, Mira’s Chief Scientific Advisor, emphasized the scientific rationale behind SKNY-1: “This is a uniquely designed molecule that addresses the biological complexity of both obesity and addiction. The early data are promising.”

Mira views the acquisition as a pivotal step toward building a scaled, innovation-driven platform focused on areas of urgent unmet need—backed by differentiated science and a clear commercial strategy.

You might like this article:Trump Crypto Advisor David Bailey Raises $300M for New Public Bitcoin Investment Firm

Tags: GrowthMIRAMoversNewsStock Market
Previous Post

Trump Crypto Advisor David Bailey Raises $300M for New Public Bitcoin Investment Firm

Next Post

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

Related Posts

scientist

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

byLuca Blaumann
October 23, 2025
0

$256 million U.S. market opportunity drives expansion as company kicks off multi-channel promotional campaign Scienture Holdings (SCNX) announced the official...

chemistry-2

Replimune Reports Promising New Data for Acral Melanoma Treatment at ESMO 2025

byLuca Blaumann
October 20, 2025
0

RP1 combined with nivolumab shows meaningful tumor response in rare and aggressive skin cancer Replimune Group (REPL), a clinical-stage biotechnology...

Praxis Announces Breakthrough Phase 3 Results for Ulixacaltamide in Essential Tremor Treatment

byLuca Blaumann
October 16, 2025
0

Positive data from Essential3 program marks major step toward first targeted therapy for millions living with essential tremor Praxis Precision...

Next Post

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Based on Your Interest

nvidia-chip
Artificial Intelligence

Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers

October 28, 2025
investing
Artificial Intelligence

Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips

October 27, 2025
Biotechnology

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

October 27, 2025

Recommended

Artificial Intelligence

Datavault AI and Wellgistics Partner to Revolutionize Prescription Tracking with Blockchain Technology

October 24, 2025
Large-Cap

AMD Shares Surge as IBM Taps Its Chips for Quantum Computing Breakthrough

October 24, 2025
Large-Cap

Intel Surges After Strong Q3 Earnings Beat, But Manufacturing Challenges Remain

October 23, 2025
Auto Manufacturers

Ford Beats Q3 Estimates but Cuts 2025 Outlook Following Supplier Fire

October 23, 2025
Biotechnology

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

October 23, 2025
Stoxpo

Follow us on social media:

Highlights

  • Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth
  • Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum
  • Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3
  • Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240
  • Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Alphabet Tops $100 Billion Quarter as AI Cloud Deals Power Record Growth

October 29, 2025

Microsoft Reports Strong Q3 Results Driven by Cloud and AI Momentum

October 29, 2025
investing

Meta Beats on Revenue, Misses EPS as One-Time Tax Charge Weighs on Q3

October 29, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.